July 2016 Br J Cardiol 2016;23:106–9 doi:10.5837/bjc.2016.025 Online First
Blandina Gomes, Kamen Valchanov, William Davies, Adam Brown, Peter Schofield
Introduction Papworth Hospital NHS Trust, Cambridge Spinal cord stimulation (SCS) therapy has been used for more than four decades in a variety of chronic pain conditions. The introduction of neurostimulation was a logical consequence of the ‘gate-control’ theory published in 1965.1 According to this model, the activation of large afferent nerve fibres inhibits pain input mediated by small fibres into the dorsal horn of the spinal cord. The goal of SCS is to attenuate discomfort by provoking paraesthesia in the same area. The European Society of Cardiology defines refractory angina as a chronic condition characterised by the presence of a
October 2014 Br J Cardiol 2014;21:131–2 doi:10.5837/bjc.2014.032 Online First
Linda van der Heiden, Joyca Lacroix, Saskia van Dantzig, Aart van Halteren
The non-adherence problem Medication adherence is defined as the extent to which a patient acts in accordance with the prescribed interval and dose of a dosing regimen.1 Subsequently, non-adherence means that the patient is not taking all their medication doses as prescribed, jeopardising the clinical outcome. Cardiovascular medications (such as statins, antihypertensives and antithrombotics) remain the most commonly prescribed agents worldwide for both primary and secondary prevention of cardiovascular diseases (CVD). Patients with low adherence rates have a significantly greater risk of sustaining cardiovascular events compared to those wi
You need to be a member to print this page.
Find out more about our membership benefits
You need to be a member to download PDF's.
Find out more about our membership benefits